Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS

Next Previous
X
Search
Trial Profile

A RANDOMIZED, OPEN-LABEL, TWO-PERIOD STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETANERCEPT ON SKIN AND JOINT DISEASE IN PSORIASIS SUBJECTS WITH PSORIATIC ARTHRITIS

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 01 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etanercept (Primary)
  • Indications Psoriasis; Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms PRESTA
  • Sponsors Pfizer; Wyeth

    • Most Recent Events

    • 03 Aug 2017 Results of pooled analysis of 10 trials (NCT00245960, NCT00111449, NCT00663052, NCT00454584) generating evidence concerning the number of patients dropping out of etanercept trials published in the British Journal of Dermatology
    • 17 Jun 2017 Results of post hoc analysis presented at the 18th Annual Congress of the European League Against Rheumatism
    • 13 Jun 2015 Results of post-hoc analysis presented at the 16th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top